Edition:
United Kingdom

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

41.89USD
25 Mar 2019
Change (% chg)

-- (--)
Prev Close
$41.89
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
8,302,607
52-wk High
$46.46
52-wk Low
$34.32

About

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business... (more)

Overall

Beta: 0.99
Market Cap(Mil.): $214,682.30
Shares Outstanding(Mil.): 5,955.13
Dividend: 0.32
Yield (%): 3.55

Financials

  PFE.N Industry Sector
P/E (TTM): 26.26 29.30 32.54
EPS (TTM): 1.37 -- --
ROI: 6.00 14.23 13.82
ROE: 13.80 15.46 15.24

Pfizer buys stake in French gene therapy firm Vivet

Pfizer Inc said on Wednesday it acquired a 15 percent stake in Vivet Therapeutics, as well as an exclusive option to fully acquire it, a deal that will give it access to the French company's experimental gene therapy for a rare genetic disorder called Wilson disease.

20 Mar 2019

UPDATE 1-Pfizer buys stake in French gene therapy firm Vivet

March 20 Pfizer Inc said on Wednesday it acquired a 15 percent stake in Vivet Therapeutics, as well as an exclusive option to fully acquire it, a deal that will give it access to the French company's experimental gene therapy for a rare genetic disorder called Wilson disease.

20 Mar 2019

Pfizer buys stake in French gene therapy firm Vivet

March 20 Pfizer Inc said on Wednesday it has acquired a 15 percent stake in Vivet Therapeutics, and has an exclusive option to fully acquire the privately held French company that develops gene therapies for liver disorders.

20 Mar 2019

FDA approves Pfizer's biosimilar to Roche's Herceptin

The U.S. Food and Drug Administration said on Monday it approved Pfizer Inc's biosimilar to Roche AG's blockbuster breast cancer treatment Herceptin.

11 Mar 2019

UPDATE 1-FDA approves Pfizer's biosimilar to Roche's Herceptin

March 11 The U.S. Food and Drug Administration said on Monday it approved Pfizer Inc's biosimilar to Roche AG's blockbuster breast cancer treatment Herceptin.

11 Mar 2019

FDA approves Pfizer's biosimilar to Roche's Herceptin

March 11 The U.S. Food and Drug Administration said on Monday it approved Pfizer Inc's biosimilar to Roche AG's blockbuster treatment for breast cancer, Herceptin.

11 Mar 2019

Pfizer unit Meridian under civil investigation by U.S. Attorney

Pfizer Inc said on Thursday it received a request for documents as part of a U.S. investigation related to quality issues involving the manufacture of auto-injectors at its Meridian Medical Technologies site.

01 Mar 2019

Pfizer unit Meridian under civil investigation by U.S. Attorney

Pfizer Inc said on Thursday it received a request for documents as part of a U.S. investigation related to quality issues involving the manufacture of auto-injectors at its Meridian Medical Technologies site.

01 Mar 2019

Pfizer unit Meridian under civil investigation by U.S. Attorney

Feb 28 Pfizer Inc said on Thursday it received a request for documents as part of a U.S. investigation related to quality issues involving the manufacture of auto-injectors at its Meridian Medical Technologies site.

01 Mar 2019

BRIEF-Pfizer Receives European Approval For Zirabev, A Biosimilar To Avastin

* PFIZER RECEIVES EUROPEAN APPROVAL FOR ZIRABEV (BEVACIZUMAB), A BIOSIMILAR TO AVASTIN

19 Feb 2019

Earnings vs. Estimates